Sarepta Therapeutics stock faces challenges as BMO survey reveals investor concerns

Sarepta Therapeutics (SRPT) faces severe investor and analyst scrutiny, with its stock down over 90% in the past year. A BMO Capital survey reveals widespread doubts about management credibility, high expectations of FDA approval withdrawal for Elevidys' non-ambulatory use, and mounting financial stability concerns regarding debt covenants. Multiple firms, including Mizuho, Leerink, Deutsche Bank, and Baird, have downgraded SRPT due to safety issues with its gene therapy, including patient deaths from liver failure and an FDA request to halt Elevidys shipments, signaling a challenging and volatile path ahead for the company.

Analysis

Sarepta Therapeutics (SRPT) is facing a severe crisis of confidence from both investors and analysts, precipitated by significant safety and management credibility issues. The company's stock has plummeted over 90% in the past year, reflecting deep-seated concerns. A BMO Capital survey of 21 buy-side investors quantifies this pessimism: 90% anticipate the FDA will withdraw approval for Elevidys in non-ambulatory use, and a staggering 85% rate management credibility at 2 out of 10 or lower, specifically citing a "lack of LGMD death disclosure." This sentiment is compounded by mounting financial concerns, with 55% of respondents expecting the company to breach EBITDA covenants required for its $600 million revolver. The negative outlook is broadly shared across Wall Street, evidenced by a wave of downgrades from Mizuho, Leerink, Deutsche Bank, and Baird, all citing fatal safety events, an FDA request to halt Elevidys shipments, and transparency failures. With six analysts revising earnings estimates downward and 75% of surveyed investors doubting that upcoming data readouts can reverse the company's trajectory, the path to recovery appears exceptionally challenging and fraught with near-term volatility.

Key Decisions for Investors

• Given the overwhelming negative sentiment and severe management credibility deficit, investors should view SRPT as an extremely high-risk security with significant potential for further downside from regulatory actions or a breach of debt covenants.
• Monitor upcoming communications from the FDA regarding Elevidys and the company's quarterly reports for any updates on its ability to meet EBITDA requirements, as these are the most critical near-term catalysts.
• Potential investors should remain on the sidelines until there is a clear resolution to the ongoing safety investigations and a demonstrable effort by the company to restore trust with regulators and the market.